NOV 002: Clinical Trials

3 trials of NOV 002, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 withdrawn. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 2, Withdrawn 1

Follow NOV 002: new trials by email Literature Review of NOV 002 trials Research Report on NOV 002

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer
Cyclophosphamide, Docetaxel, Doxorubicin - Breast Cancer
Phase 2CompletedUniversity of Miami412007-06-042018-01-02
Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer
NOV-002, Carboplatin - Ovarian Cancer
Phase 2CompletedCellectar Biosciences, Inc.152006-07-012015-03-10
NOV-002 in Myelodysplastic Syndrome (MDS)
NOV-002 - Leukemia, Myelodysplastic Syndrome
Phase 2WithdrawnM.D. Anderson Cancer Center2012-07-30

Conditions studied

Breast Neoplasms (1)  ·  Inflammatory Breast Neoplasms (1)  ·  Leukemia (1)  ·  Myelodysplastic Syndromes (1)  ·  Ovarian Neoplasms (1)

Sponsors

Cellectar Biosciences, Inc. (1)  ·  M.D. Anderson Cancer Center (1)  ·  University of Miami (1)

Countries

United States (2)

Top investigators

Alberto Montero, MD (1)  ·  Carolyn Kransner, MD (1)  ·  Gautam Borthakur, MBBS (1)  ·  Keisuke Shirai, MD (1)

Results publications

PMID 22138748